SCOTTSDALE, Ariz., July 7 /PRNewswire/ -- Americans aren't willing to give up aesthetic injections and interest is growing, whether as a means to stay competitive in today's job market or simply to maintain a youthful image, the demand and want is strong. At the time of a recent Kelton Research* survey more than 40 percent of respondents were interested in receiving aesthetic botulinum toxin injections within the next six months.(1)
Despite clear interest, many expressed reluctance to having a botulinum toxin injection. In fact, one-third of those who had not yet received the treatment were worried that it would prevent them from being able to make natural facial expressions.(1)
Sixty-three percent of survey respondents who would ever consider receiving botulinum toxin injections cited that a guarantee of natural-looking results would influence their decision, demonstrating a desire for retaining a natural-looking face, and more natural-looking expressions following injection.(1)
Other top factors included more affordable costs, longer-lasting and faster-acting results.(2)
The poll found that of the respondents who had never undergone botulinum toxin injections, 36% said that their concern about no longer having a natural look had prevented them from receiving the treatment in the past.(1) Almost 60 percent of those surveyed who had not ever received an injection stated that they'd be likely to if the cost of treatment was more affordable.(1) And, of the respondents who had botulinum toxin injections, three in ten reported not seeing noticeable results for at least a week(1) and thirty percent of polled respondents said that having immediate results, such as within 24-48 hours, would positively influence their decision to undergo treatment.(2)
According to Florida dermatologist Dr. Susan Weinkle, patients want value and rapid results at a fair price. "My patients are looking for a treatment that will not make them look obvious or overdone and they want these natural looking results fast."
They are in luck: after extensive testing and clinical results, a new Botulinum Toxin A is now on the market. Dysport(TM) has been approved by the FDA for use in the United States for the temporary improvement in the appearance of moderate to severe glabellar lines - the vertical lines between the eyebrows - in adult men and women 65 or younger.
The benefits of Dysport(TM) include:
• Duration - results lasting up to four months
• Demonstrated efficacy with four repeat treatments (proving results following each treatment)
• Demonstrated safety with 12 repeat treatments
• No evidence of neutralizing antibodies
• Clinical trials included both subjects who have and have not previously been treated with a Botulinum Toxin. There was no difference in results among the two groups
•Large patient population - 4,800 treatments in 2,900 patients (with an ethnically diverse population)
*About the 2009 Botulinum Toxin survey:
Sample: 600 U.S. adults ages 25-60 with a household income of $50,000 or more, including 570 females and 300 botulinum toxin users and 300 aware of at least one nonsurgical aesthetic procedure or treatment.(2)
References:
1. Kelton Research. Botulinum Toxin Survey NewsWorthy Analysis. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.
2. Kelton Research. Botulinum Toxin Survey Topline Report. February--March 2009. Data on file, Medicis Pharmaceutical Corporation.
Important Safety Information
Dysport(TM) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients.
Botulinum toxin effects may spread beyond the site of local injection to produce systemic symptoms of botulism such as swallowing and breathing difficulties that can occur within hours to weeks of injection. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults, particularly in those patents who have underlying conditions that would predispose them to these symptoms. In clinical trials, the most frequently reported adverse effects (>2%) are headache, nasopharyngitis and upper respiratory tract infection.
Dysport(TM) is not recommended for children or pregnant women. Re-treatment with Dysport(TM) should be administered no more than every three months.
SOURCE Medicis Aesthetics Inc
No comments:
Post a Comment